Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Polls

Editorial Advisory Board

Partners

Subscribe

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Articles

The study reported that UST leads in dose escalation frequency, but also had lower discontinuation rates when compared to ADA and ETN.

Study Compares Dose Escalation with Biologics in Psoriasis

A recent review found the LDI shows significant symptom improvement, but needs further study for long-term maintenance.

Isotretinoin’s Role in Rosacea Management

Publishing Excellence Runs More Than Skin Deep

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Dermatology Times spoke with Leah Howard, JD, of the NPF, and Trisha, the mother of a young girl with psoriasis, to discuss Otezla's implications in the therapeutic landscape.

Availability of Apremilast in US for Pediatric Patients Opens Avenues for Expanded Treatment Options and Oral Therapy

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Twitter

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

View

Beyond the Stigma: Patient Stories in Vitiligo Management

Case-Based Insights: Addressing Location-Specific Concerns and Treatment Challenges in Vitiligo Management

Videos

various aspects of vitiligo management through case-based discussions and insights including navigating emotional and clinical challenges to balancing treatment options with coverage constraints.

Ted Lain, MD, MBA, FAAD offers insights into navigating the emotional and clinical challenges in vitiligo management. 

Insights into Navigating the Emotional and Clinical Challenges in Vitiligo Management

Ted Lain, MD, MBA, FAAD discusses balancing vitiligo treatments with coverage challenges.

Balancing Vitiligo Treatments with Coverage Challenges

Ted Lain, MD, MBA, FAAD discusses a case which addresses location-specific concerns and treatment challenges in vitiligo management. 

Ted Lain, MD, MBA, FAAD discusses navigating the treatment paradigm for vitiligo. 

Navigating the Treatment Paradigm for Vitiligo: Efficacy, MOA, and Long-Term Use of FDA-Approved Topical Ruxolitinib

Case Based Peer Perspectives

Case-Based Insights: Addressing Location-Specific Concerns and Treatment Challenges in Vitiligo Management

EP: 1.Insights into Navigating the Emotional and Clinical Challenges in Vitiligo Management

EP: 2.Balancing Vitiligo Treatments with Coverage Challenges

EP: 3.Case-Based Insights: Addressing Location-Specific Concerns and Treatment Challenges in Vitiligo Management

EP: 4.Navigating the Treatment Paradigm for Vitiligo: Efficacy, MOA, and Long-Term Use of FDA-Approved Topical Ruxolitinib